These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

734 related articles for article (PubMed ID: 16530575)

  • 41. Predictors of mortality in HIV-1 infected children on antiretroviral therapy in Kenya: a prospective cohort.
    Wamalwa DC; Obimbo EM; Farquhar C; Richardson BA; Mbori-Ngacha DA; Inwani I; Benki-Nugent S; John-Stewart G
    BMC Pediatr; 2010 May; 10():33. PubMed ID: 20482796
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study.
    Ananworanich J; Siangphoe U; Hill A; Cardiello P; Apateerapong W; Hirschel B; Mahanontharit A; Ubolyam S; Cooper D; Phanuphak P; Ruxrungtham K
    J Acquir Immune Defic Syndr; 2005 Aug; 39(5):523-9. PubMed ID: 16044002
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.
    Pujades-Rodríguez M; O'Brien D; Humblet P; Calmy A
    AIDS; 2008 Jul; 22(11):1305-12. PubMed ID: 18580610
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predicting mortality in HIV-infected children initiating highly active antiretroviral therapy in a resource-deprived setting.
    Nugent J; Edmonds A; Lusiama J; Thompson D; Behets F;
    Pediatr Infect Dis J; 2014 Nov; 33(11):1148-55. PubMed ID: 24945879
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort.
    Zolfo M; Schapiro JM; Phan V; Koole O; Thai S; Vekemans M; Fransen K; Lynen L
    AIDS Res Hum Retroviruses; 2011 Jul; 27(7):727-35. PubMed ID: 20854169
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Low versus high CD4 cell count as starting point for introduction of antiretroviral treatment in resource-poor settings: a scenario-based analysis.
    Bogaards JA; Weverling GJ; Geskus RB; Miedema F; Lange JM; Bossuyt PM; Goudsmit J
    Antivir Ther; 2003 Feb; 8(1):43-50. PubMed ID: 12713063
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia.
    Ferradini L; Laureillard D; Prak N; Ngeth C; Fernandez M; Pinoges L; Puertas G; Taburet AM; Ly N; Rouzioux C; Balkan S; Quillet C; Delfraissy JF
    AIDS; 2007 Nov; 21(17):2293-301. PubMed ID: 18090277
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.
    Paredes R; Mocroft A; Kirk O; Lazzarin A; Barton SE; van Lunzen J; Katzenstein TL; Antunes F; Lundgren JD; Clotet B
    Arch Intern Med; 2000 Apr; 160(8):1123-32. PubMed ID: 10789605
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
    Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
    Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Non-uptake of highly active antiretroviral therapy among patients with a CD4 count < 350 cells/μL in the UK.
    Kober C; Johnson M; Fisher M; Hill T; Anderson J; Bansi L; Gompels M; Palfreeman A; Dunn D; Gazzard B; Gilson R; Post F; Phillips AN; Walsh J; Orkin C; Delpech V; Ainsworth J; Leen C; Sabin CA;
    HIV Med; 2012 Jan; 13(1):73-8. PubMed ID: 22106827
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical outcome of HIV-infected patients with sustained virologic response to antiretroviral therapy: long-term follow-up of a multicenter cohort.
    Gutierrez F; Padilla S; Masiá M; Iribarren JA; Moreno S; Viciana P; Muñoz L; Gómez Sirvent JL; Vidal F; López-Aldeguer J; Blanco JR; Leal M; Rodríguez-Arenas MA; Perez Hoyos S;
    PLoS One; 2006 Dec; 1(1):e89. PubMed ID: 17183720
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.
    Wood E; Hogg RS; Yip B; Harrigan PR; O'Shaughnessy MV; Montaner JS
    Ann Intern Med; 2003 Nov; 139(10):810-6. PubMed ID: 14623618
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Treatment interruption in 30 HIV-infected patients with successful viral suppression under highly active antiretroviral treatment].
    Pavie J; Porcher R; Fournier S; André F; Tournoux C; Palmer P; Rabian C; Jean-Michel M
    Presse Med; 2005 Jun; 34(10 Suppl):1S8-13. PubMed ID: 16025661
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Monitoring of HIV viral load, CD4 cell count, and clinical assessment versus clinical monitoring alone for antiretroviral therapy in low-resource settings (Stratall ANRS 12110/ESTHER): a cost-effectiveness analysis.
    Boyer S; March L; Kouanfack C; Laborde-Balen G; Marino P; Aghokeng AF; Mpoudi-Ngole E; Koulla-Shiro S; Delaporte E; Carrieri MP; Spire B; Laurent C; Moatti JP;
    Lancet Infect Dis; 2013 Jul; 13(7):577-86. PubMed ID: 23602084
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: a nationwide population-based cohort study.
    Thorsteinsson K; Ladelund S; Jensen-Fangel S; Johansen IS; Katzenstein TL; Pedersen G; Storgaard M; Obel N; Lebech AM
    BMC Infect Dis; 2012 Nov; 12():293. PubMed ID: 23140254
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings.
    Marazzi MC; Liotta G; Germano P; Guidotti G; Altan AD; Ceffa S; Lio MM; Nielsen-Saines K; Palombi L
    AIDS Res Hum Retroviruses; 2008 Apr; 24(4):555-60. PubMed ID: 18366314
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy in Perinatally HIV-Infected, Treatment-Naïve Adolescents in Asia.
    Boettiger DC; Sudjaritruk T; Nallusamy R; Lumbiganon P; Rungmaitree S; Hansudewechakul R; Kumarasamy N; Bunupuradah T; Saphonn V; Truong KH; Yusoff NKN; Do VC; Nguyen LV; Razali KAM; Fong SM; Kurniati N; Kariminia A
    J Adolesc Health; 2016 Apr; 58(4):451-459. PubMed ID: 26803201
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART.
    Hogg RS; Bangsberg DR; Lima VD; Alexander C; Bonner S; Yip B; Wood E; Dong WW; Montaner JS; Harrigan PR
    PLoS Med; 2006 Sep; 3(9):e356. PubMed ID: 16984218
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy.
    Puthanakit T; Kerr S; Ananworanich J; Bunupuradah T; Boonrak P; Sirisanthana V
    Pediatr Infect Dis J; 2009 Jun; 28(6):488-92. PubMed ID: 19504731
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mortality and loss to follow-up among HIV-infected persons on long-term antiretroviral therapy in Latin America and the Caribbean.
    Carriquiry G; Fink V; Koethe JR; Giganti MJ; Jayathilake K; Blevins M; Cahn P; Grinsztejn B; Wolff M; Pape JW; Padgett D; Madero JS; Gotuzzo E; McGowan CC; Shepherd BE
    J Int AIDS Soc; 2015; 18(1):20016. PubMed ID: 26165322
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.